CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for TriSalus Life Sciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

TriSalus Life Sciences Inc
6272 W. 91st Ave.
Phone: (415) 336-8917p:415 336-8917 WESTMINSTER, CO  80031  United States Ticker: TLSITLSI
Business Summary
TriSalus Life Sciences, Inc. is an oncology focused medical technology business providing drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. Its two Food and Drug Administration (FDA) cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. Additionally, the Company is exploring the integration of its technology with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of liver and pancreatic indications.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Non-Executive Chairman of the Board Mats L.Wahlstrom 69 8/10/2023 8/10/2023
President, Chief Executive Officer, Director Mary T.Szela 59 8/10/2023 8/10/2023
Chief Financial Officer, Director SeanMurphy 70 8/10/2023 8/10/2023
9 additional Officers and Directors records available in full report.

Business Names
Business Name
MedTech Acquisition Corporation
MTAC
MTACU
TLSI

General Information
Number of Employees: 112 (As of 3/5/2024)
Outstanding Shares: 26,758,295 (As of 4/3/2024)
Shareholders: 136
Stock Exchange: NASD
Federal Tax Id: 853009869
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 8, 2024